Altimmune, Inc. (NASDAQ:ALT - Get Free Report)'s stock price rose 6.3% on Tuesday . The stock traded as high as $10.70 and last traded at $10.49. Approximately 553,781 shares were traded during trading, a decline of 91% from the average daily volume of 6,220,923 shares. The stock had previously closed at $9.87.
Analysts Set New Price Targets
ALT has been the topic of several recent research reports. The Goldman Sachs Group initiated coverage on Altimmune in a report on Wednesday, January 24th. They set a "neutral" rating and a $13.00 price target on the stock. B. Riley restated a "buy" rating and set a $20.00 price target on shares of Altimmune in a report on Tuesday, February 13th. Finally, HC Wainwright restated a "buy" rating and set a $15.00 price target on shares of Altimmune in a report on Friday, December 1st.
Get Our Latest Analysis on Altimmune
Altimmune Price Performance
The company has a market capitalization of $574.90 million, a price-to-earnings ratio of -6.81 and a beta of 0.08. The stock has a fifty day simple moving average of $10.36 and a 200-day simple moving average of $6.13.
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the company. FNY Investment Advisers LLC acquired a new position in Altimmune in the 4th quarter valued at $35,000. Russell Investments Group Ltd. raised its stake in Altimmune by 1,150.9% in the 4th quarter. Russell Investments Group Ltd. now owns 4,303 shares of the company's stock valued at $48,000 after purchasing an additional 3,959 shares during the last quarter. Osaic Holdings Inc. raised its stake in Altimmune by 77.3% in the 2nd quarter. Osaic Holdings Inc. now owns 7,834 shares of the company's stock valued at $28,000 after purchasing an additional 3,416 shares during the last quarter. Horizon Wealth Management LLC acquired a new position in Altimmune in the 4th quarter valued at $112,000. Finally, Deuterium Capital Management LLC acquired a new position in Altimmune in the 4th quarter valued at $112,000. 66.99% of the stock is owned by institutional investors and hedge funds.
Altimmune Company Profile
(
Get Free Report)
Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Altimmune, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Altimmune wasn't on the list.
While Altimmune currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
